Looking at Chimeric Therapeutics Limited's (ASX:CHM ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by ...

Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational ...

Paul Hopper bought 200.00m shares over the last 12 months at an average price of AU$0.008. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on ...

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T ™) ...

Chimeric antigen receptor-T (CAR-T) cell therapy ... which are derived from the patient's own cells. 30 SynKIR-110, developed by Verismo Therapeutics, is another innovative CAR-T cell therapy ...

StockNews.com began coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Free Report) in a research report report ...

In a report released today, Michael Yee from Jefferies downgraded CARGO Therapeutics, Inc. (CRGX – Research Report) to a Hold, with a price ...

China Universal Asset Management Co. Ltd. bought a new stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor ...